Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.50+0.04 (+1.16%)
Close on Nov 18, 2026Market cap $226.67MP/E –Yield –
Immuneering free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Immuneering's free cash flow for the twelve months ending Sep 30, 2026 was -$61.81M. For fiscal 2025 it was -$45.49M. The highest annual figure on record is -$14.67M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.49M | – |
| FY2024 | Dec 31, 2024 | -$55.08M | – |
| FY2023 | Dec 31, 2023 | -$49.31M | – |
| FY2022 | Dec 31, 2022 | -$44.84M | – |
| FY2021 | Dec 31, 2021 | -$30.91M | – |
| FY2020 | Dec 31, 2020 | -$14.67M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$16.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$16.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.53M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.95M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.45M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.61M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.25M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.46M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.49M | – |
See a number that looks wrong?